Obsidian Therapeutics Appoints Dana Alexander as Chief Technical Officer [Yahoo! Finance]
AlloVir, Inc. (ALVR)
Company Research
Source: Yahoo! Finance
gene therapies, today announced the appointment of Dana Alexander as Chief Technical Officer. "Dana has over two decades of operational expertise across cell therapy, gene therapy and biologics process development and chemistry, manufacturing, and controls (CMC), from Phase 1 through commercialization," said Madan Jagasia, M.D., Chief Executive Officer of Obsidian. "His leadership will be instrumental as we continue leveraging our proprietary cytoDRiVE ® platform to advance our lead tumor-infiltrating lymphocyte (TIL) cell therapy, OBX-115, through clinical development for the treatment of solid tumors. We are delighted to welcome Dana to our management team." "I am thrilled to be joining the highly accomplished and passionate Obsidian leadership team and to have the opportunity to grow and expand the company's CMC capabilities," said Mr. Alexander. "I look forward to collaborating with the team to advance OBX-115 and maximizing the company's platform for manufacturing patient-spe
Show less
Read more
Impact Snapshot
Event Time:
ALVR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALVR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALVR alerts
High impacting AlloVir, Inc. news events
Weekly update
A roundup of the hottest topics
ALVR
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines – ALVRGlobeNewswire
- Shareholders of AlloVir, Inc. Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVRAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVRPR Newswire
- AlloVir, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALVRAccesswire
- ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AllovirGlobeNewswire
ALVR
Earnings
- 5/13/24 - Miss
ALVR
Sec Filings
- 5/17/24 - Form 144
- 5/17/24 - Form 144
- 5/17/24 - Form 144
- ALVR's page on the SEC website